Ivrea 6mg Tablet contains Ivermectin, an antiparasitic agent used primarily for the treatment of various parasitic infections. Ivermectin acts by binding selectively to glutamate-gated chloride ion channels present in invertebrate nerve and muscle cells, leading to increased permeability to chloride ions, hyperpolarization, and subsequent paralysis and death of the parasite. Ivrea is indicated for the treatment of onchocerciasis (river blindness), strongyloidiasis, and other infections caused by susceptible parasites such as certain types of intestinal roundworms and ectoparasites. The tablet formulation provides a convenient oral dosage form, with a standard dose of 6 mg per tablet, typically administered as a single dose or as prescribed based on the patient’s weight and the specific infection being treated. Ivrea should be used under medical supervision, with dosage adjustments in special populations such as children and patients with hepatic impairment. Common adverse effects may include mild gastrointestinal disturbances, dizziness, and transient skin reactions. It is contraindicated in patients with known hypersensitivity to Ivermectin or any excipients. Caution is advised during pregnancy and lactation, and potential drug interactions should be evaluated prior to administration. Ivrea 6mg Tablet offers an effective and well-tolerated option for the management of parasitic infections in clinical practice.